Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Pralatrexate
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : CASI Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : The partnership aims for the manufacturing and advancement of iTolerance's Streptavidin-FasL (SA-FasL) fusion protein, a crucial component of the proprietary iTOL-100 platform technology towards first in human clinical study for lead program, iTOL-102.
Brand Name : Folotyn
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 01, 2023
Lead Product(s) : Pralatrexate
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : CASI Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Study Phase : Approved
Recipient : Onxeo
Deal Size : $6.6 million
Deal Type : Agreement
Details : The new Agreement grants Acrotech a royalty-free license to belinostat in all other territories including the United States, Canada, Mexico, and India.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : $6.6 million
April 06, 2020
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Highest Development Status : Approved
Recipient : Onxeo
Deal Size : $6.6 million
Deal Type : Agreement
LOOKING FOR A SUPPLIER?